MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
STRATA Skin Sciences Net Income 2011-2026 | SSKN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income STRATA Skin Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.55 M | -2.71 M | -4.41 M | -3.79 M | -4.03 M | -18.8 M | -3.34 M | -24.9 M | -14.1 M | -25.9 M | -22.7 M | -20.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.71 M | -25.9 M | -12.6 M |
Quarterly Net Income STRATA Skin Sciences
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.62 M | - | -2.07 M | -99 K | -3.37 M | - | -1.05 M | -3.15 M | -2.84 M | - | -995 K | -1.89 M | -2.5 M | - | -521 K | 1.08 M | -2.42 M | - | -1.25 M | -1.68 M | -1.04 M | - | -860 K | -1.08 M | -1.33 M | - | -608 K | -1.63 M | -2.08 M | - | -19.1 M | 2.46 M | -3.97 M | - | -1.51 M | 498 K | -1.44 M | - | -9.23 M | -7.85 M | -7.27 M | - | -2.29 M | 14.1 M | -7.98 M | - | -7.4 M | -7.42 M | -6.51 M | -6.08 M | -5.36 M | -5.48 M | -5.75 M | -4.52 M | -6.11 M | -4.81 M | -4.94 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.1 M | -19.1 M | -3.13 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 13.11 | 0.23 % | $ 1.77 B |  USA |
 |
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
-157 M | - | - | $ 10.2 M | USA |
 |
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
Second Sight Medical Products
EYES
|
-26.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
7.54 M | $ 25.71 | 2.43 % | $ 217 M | USA |
 |
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | $ 3.32 | 0.3 % | $ 124 M |  France |
 |
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
-25.5 M | $ 11.18 | 8.12 % | $ 317 M | USA |
 |
Helius Medical Technologies
HSDT
|
-8.85 M | $ 2.04 | 3.03 % | $ 1.24 M | USA |
 |
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.61 | -4.04 % | $ 38 M | USA |
 |
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | USA |
 |
Inspire Medical Systems
INSP
|
145 M | $ 56.14 | 5.11 % | $ 1.65 B | USA |
 |
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | USA |
 |
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Dynatronics Corporation
DYNT
|
-10.9 M | - | 14.99 % | $ 929 K | USA |
 |
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
-242 M | $ 60.1 | 2.0 % | $ 3.28 B |  Britain |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 15.06 | 2.87 % | $ 353 M | USA |
 |
Butterfly Network
BFLY
|
-72.5 M | $ 4.79 | -2.64 % | $ 1.01 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
538 M | $ 90.18 | 2.72 % | $ 12.2 B | USA |
 |
Delcath Systems
DCTH
|
2.7 M | $ 10.38 | 1.67 % | $ 372 M | USA |
 |
NanoVibronix
NAOV
|
-18.2 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
47.1 M | $ 36.66 | 1.95 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
103 M | $ 88.51 | 5.78 % | $ 3.07 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 83.5 | 2.81 % | $ 48.8 B | USA |
 |
LENSAR
LNSR
|
-34.3 M | $ 5.23 | -2.97 % | $ 62.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
-54 M | $ 1.28 | 6.67 % | $ 52.1 M | USA |
 |
MiMedx Group
MDXG
|
48.6 M | $ 3.36 | 8.91 % | $ 497 M | USA |
 |
Myomo
MYO
|
-15.6 M | $ 0.86 | 8.54 % | $ 36 M | USA |
 |
Cutera
CUTR
|
-57.2 M | - | -10.19 % | $ 1.99 M | USA |
 |
NuVasive
NUVA
|
40.4 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
-113 M | - | - | $ 217 M | USA |
 |
Natus Medical Incorporated
NTUS
|
13.2 M | - | 1.94 % | $ 1.05 B | USA |